Statement of Comprehensive Income
Comprehensive income is the change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owners sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
Paying user area
Try for free
Pfizer Inc. pages available for free this week:
- Balance Sheet: Liabilities and Stockholders’ Equity
- Cash Flow Statement
- Analysis of Short-term (Operating) Activity Ratios
- Enterprise Value (EV)
- Enterprise Value to EBITDA (EV/EBITDA)
- Price to FCFE (P/FCFE)
- Current Ratio since 2005
- Debt to Equity since 2005
- Total Asset Turnover since 2005
- Price to Earnings (P/E) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Pfizer Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Pfizer Inc., consolidated statement of comprehensive income
US$ in millions
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
- Net Income Before Allocation to Noncontrolling Interests
- The net income exhibits significant volatility over the period. It increased sharply from 9,652 million US$ in 2020 to a peak of 31,407 million US$ in 2022, followed by a steep decline to 2,158 million US$ in 2023, then rebounding to 8,062 million US$ in 2024. This suggests fluctuating profitability, likely influenced by external or operational factors.
- Foreign Currency Translation Adjustments
- The net foreign currency translation adjustments showed a negative trend from 1,036 million US$ in 2020 to losses of -2,204 million US$ in 2022. This was followed by a recovery to a positive 485 million US$ in 2023 but then turned negative again at -124 million US$ in 2024. This indicates continued exposure to foreign exchange fluctuations impacting the company’s financials inconsistently.
- Unrealized Holding Gains (Losses) on Derivative Financial Instruments
- A positive trend is observed with gains increasing from a loss of -494 million US$ in 2020 to gains of 1,261 million US$ in 2022. Gains then decreased but remained positive at 514 million US$ in 2023 and 403 million US$ in 2024. Reclassification adjustments showed a marked negative adjustment in 2022 (-1,792 million US$) followed by smaller negative adjustments in subsequent years, showing volatility in derivative instrument valuations and their impact on income.
- Unrealized Holding Gains (Losses) on Available-for-Sale Securities
- This category experienced a decline from gains of 316 million US$ in 2020 to increasing losses peaking at -1,142 million US$ in 2022, with minor losses thereafter. Corresponding reclassification adjustments were negative in early years and showed a large positive spike (1,583 million US$) in 2022, suggesting that some gains or losses were realized affecting reported earnings.
- Actuarial Gains (Losses) and Related Reclassifications
- Actuarial losses were significant in 2020 (-847 million US$) with related positive reclassification adjustments partially offsetting these losses. From 2021 onward, actuarial gains or losses data is not available. The prior service costs and other related items fluctuated minimally across the years, indicating relative stability in pension or benefit plan assumptions.
- Benefit Plans
- Benefit plan related losses sharply decreased from -709 million US$ in 2020 to less pronounced values in subsequent years, with a positive turn to 63 million US$ in 2024. This reflects changing pension or benefit plan liabilities or funding status improving over time.
- Other Comprehensive Income (Loss) Before Allocation to Noncontrolling Interests
- The other comprehensive income experienced negative impacts in 2021 and 2022 (-590 million US$ and -2,422 million US$, respectively), followed by a recovery to a positive value of 330 million US$ in 2023 and 116 million US$ in 2024. This reflects recovery from adverse market or foreign currency effects affecting comprehensive income components.
- Comprehensive Income
- Comprehensive income showed a trend similar to net income, with substantial growth from 9,666 million US$ in 2020 to 28,985 million US$ in 2022, followed by a significant decline in 2023 (2,488 million US$) and a partial recovery in 2024 (8,178 million US$). This pattern was consistent for both amounts attributable to Pfizer Inc. and after allocation to noncontrolling interests, demonstrating volatility in overall financial performance but with notable resiliency.